Who are AMG 386 with or without Trastuzumab's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): VABYSMO.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/amg-386-with-or-without-trastuzumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

AMG 386 with or without Trastuzumab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AMG 386 with or without Trastuzumab (AMG 386 with or without Trastuzumab) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiopoietin-2 inhibitor. Area: Oncology.

phase 2 Angiopoietin-2 inhibitor Angiopoietin-2 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

AMG 386 with or without Trastuzumab (AMG 386 with or without Trastuzumab) — QuantumLeap Healthcare Collaborative. AMG 386 is an angiopoietin-2 (Ang-2) inhibitor that works by binding to Ang-2 and preventing its interaction with its receptor, thereby inhibiting angiogenesis.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
AMG 386 with or without Trastuzumab TARGET	AMG 386 with or without Trastuzumab	QuantumLeap Healthcare Collaborative	phase 2	Angiopoietin-2 inhibitor	Angiopoietin-2
VABYSMO	FARICIMAB-SVOA	GENENTECH INC	marketed		Angiopoietin-2, Vascular endothelial growth factor A

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiopoietin-2 inhibitor class)

Amgen · 1 drug in this class
QuantumLeap Healthcare Collaborative · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AMG 386 with or without Trastuzumab — Competitive Intelligence Brief. https://druglandscape.com/ci/amg-386-with-or-without-trastuzumab. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab